Answers are grounded in this paper and cite their sources.
ADVERTISEMENT RETURN TO ISSUEPREVPerspectiveNEXTUrotensin-II Receptor Modulators as Potential DrugsBruce E. Maryanoff*† and William A. Kinney‡View Author Information† Johnson & Johnson Pharmaceutical Research & Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776‡ Pennsylvania Biotechnology Center, 3805 Old Easton Road, Doylestown, Pennsylvania 18902*To whom correspondence should be addressed. Phone: 267-980-3512. Fax: 858-784-2798. E-mail: [email protected], [email protected]Cite this: J. Med. Chem. 2010, 53, 7, 2695–2708Publication Date (Web):December 31, 2009Publication History Received28 August 2009Published online31 December 2009Published inissue 8 April 2010https://pubs.acs.org/doi/10.1021/jm901294uhttps://doi.org/10.1021/jm901294ureview-articleACS PublicationsCopyright © 2009 American Chemical SocietyRequest reuse permissionsArticle Views1778Altmetric-Citations37LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstract
No takes yet. Share an insight, caveat, or question.
Maryanoff et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: